[go: up one dir, main page]

PE20150128A1 - Moduladores del transporte nuclear y usos de los mismos - Google Patents

Moduladores del transporte nuclear y usos de los mismos

Info

Publication number
PE20150128A1
PE20150128A1 PE2014001997A PE2014001997A PE20150128A1 PE 20150128 A1 PE20150128 A1 PE 20150128A1 PE 2014001997 A PE2014001997 A PE 2014001997A PE 2014001997 A PE2014001997 A PE 2014001997A PE 20150128 A1 PE20150128 A1 PE 20150128A1
Authority
PE
Peru
Prior art keywords
modulators
alkyl
nuclear transportation
refers
nuclear
Prior art date
Application number
PE2014001997A
Other languages
English (en)
Inventor
Vincent P Sandanayaka
Sharon Shechter
Sharon Shacham
Dilara Mccauley
Erkan Baloglu
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49448240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150128(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of PE20150128A1 publication Critical patent/PE20150128A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Referida a un derivado de triazol de Formula l y sales farmaceuticamente aceptables de los mismos, donde R1 es H o alquilo C1-C4; R2 es O o S; R3 es alquilo C1-C6, N(R4)-(cicloalquilo C3-C6), entre otros; R4 es H o alquilo C1-C4. Tambien esta referida a una composicion farmaceutica. Dichos compuestos son moduladores del transporte nuclear y son utiles en el tratamiento de transtornos neoplasicos
PE2014001997A 2012-05-09 2013-05-09 Moduladores del transporte nuclear y usos de los mismos PE20150128A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644802P 2012-05-09 2012-05-09
US201361798188P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20150128A1 true PE20150128A1 (es) 2015-02-23

Family

ID=49448240

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001997A PE20150128A1 (es) 2012-05-09 2013-05-09 Moduladores del transporte nuclear y usos de los mismos

Country Status (33)

Country Link
US (10) US9266843B2 (es)
EP (3) EP2858991B1 (es)
JP (5) JP6195909B2 (es)
KR (5) KR102095429B1 (es)
CN (1) CN104428295B (es)
AU (5) AU2013259384B2 (es)
BR (1) BR112014027860B8 (es)
CA (1) CA2872190C (es)
CL (1) CL2014003054A1 (es)
CO (1) CO7190242A2 (es)
CY (2) CY1120832T1 (es)
DK (2) DK2858991T3 (es)
EA (1) EA036639B1 (es)
ES (2) ES2794866T3 (es)
GE (1) GEP20237477B (es)
HK (1) HK1209420A1 (es)
HR (2) HRP20181838T1 (es)
HU (2) HUE040427T2 (es)
IN (1) IN2014DN09434A (es)
LT (2) LT3404027T (es)
ME (1) ME03795B (es)
MX (1) MX364992B (es)
NZ (1) NZ702663A (es)
PE (1) PE20150128A1 (es)
PL (2) PL3404027T3 (es)
PT (2) PT3404027T (es)
RS (2) RS58058B1 (es)
SG (1) SG11201407268SA (es)
SI (2) SI3404027T1 (es)
SM (2) SMT201800686T1 (es)
UA (2) UA124922C2 (es)
WO (1) WO2013170068A2 (es)
ZA (1) ZA202004892B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011222531B2 (en) 2010-03-05 2015-03-26 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
WO2012099807A1 (en) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
CN103842340B (zh) 2011-07-29 2017-09-22 卡尔约药物治疗公司 核转运调节剂及其应用
RS56823B1 (sr) 2011-07-29 2018-04-30 Karyopharm Therapeutics Inc Modulatori nukleusnog transporta koji sadrže hidrazid i njihove upotrebe
SMT201800686T1 (it) 2012-05-09 2019-01-11 Biogen Ma Inc Modulatori di trasporto nucleare e loro usi
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
TWI662030B (zh) 2013-01-15 2019-06-11 英塞特控股公司 適用作ｐｉｍ激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
WO2014144772A1 (en) * 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
JP6730922B2 (ja) 2013-06-21 2020-07-29 カリオファーム セラピューティクス，インコーポレイテッド 核内輸送調節因子およびその使用
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
CR20160135A (es) 2013-08-23 2016-08-05 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim
US10811156B2 (en) * 2014-05-13 2020-10-20 Qsa Global Inc. Device and method for enhanced iridium gamma radiation sources
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016025904A1 (en) 2014-08-15 2016-02-18 Karyopharm Therapeutics Inc. Polymorphs of selinexor
KR101734529B1 (ko) 2015-05-08 2017-05-11 건국대학교 산학협력단 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
EP3341079A4 (en) * 2015-08-25 2019-05-08 President and Fellows of Harvard College METHOD AND COMPOSITIONS RELATED TO DIAGNOSIS AND TREATMENT OF CANCER
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
WO2017117529A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017151587A1 (en) * 2016-02-29 2017-09-08 Ohio State Innovation Foundation Aza-peptide aldehydes and ketones
EP3429690A4 (en) * 2016-03-16 2019-10-23 Ionis Pharmaceuticals, Inc. METHOD FOR MODULATING KEAP1
WO2017190087A1 (en) 2016-04-30 2017-11-02 Envision Diagnostics, Inc. Medical devices, systems, and methods for performing eye exams and eye tracking
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019137381A1 (en) 2018-01-10 2019-07-18 Xw Laboratories, Inc. Prodrugs of ketamine, compositions and uses thereof
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
CN113365640A (zh) 2018-12-06 2021-09-07 比奥根Ma公司 引导肌萎缩侧索硬化症的治疗性干预的神经丝蛋白
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
CN109928939A (zh) * 2019-02-27 2019-06-25 上海卡洛化学有限公司 一种2,2,6,6-四甲基吗啉的制备方法
WO2020223678A1 (en) * 2019-05-01 2020-11-05 Karyopharm Therapeutics Inc. Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors
CN111145135B (zh) * 2019-12-30 2021-08-10 腾讯科技（深圳）有限公司 一种图像去扰处理方法、装置、设备及存储介质
DE112022001910T5 (de) 2021-04-01 2024-01-25 Alps Alpine Co., Ltd. Vorrichtung zur erkennung einer betätigung
JP2024531204A (ja) 2021-08-13 2024-08-29 エックスダブリューファーマ リミテッド ケタミン誘導体の医薬組成物及び経口剤形
TWI857509B (zh) * 2022-03-07 2024-10-01 高雄醫學大學 用於治療 ｂ 型肝炎病毒感染的方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
AU4368996A (en) 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
CA2229617A1 (en) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation
CA2250002C (en) 1996-04-04 2008-03-25 Shionogi & Co., Ltd. Cephem compounds and drugs containing the compounds
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
AU736854B2 (en) 1996-04-25 2001-08-02 Nissan Chemical Industries Ltd. Ethylene derivatives and pesticides containing said derivatives
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
WO1999050264A1 (fr) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Derives de quinazoline
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
DE60115279T2 (de) * 2000-09-29 2006-12-28 Topotarget Uk Ltd., Abingdon Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren
JP3608050B2 (ja) 2001-07-24 2005-01-05 トヨタ自動車株式会社 ロールオーバ判別装置
JP3795044B2 (ja) 2001-09-14 2006-07-12 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
WO2004037248A2 (en) 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
CN1731994A (zh) 2002-11-01 2006-02-08 武田药品工业株式会社 预防或治疗神经病的药剂
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
CA2504941C (en) 2002-11-08 2012-06-26 Neurogen Corporation 3-substituted-6-aryl pyridines
EP1599447A1 (en) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
KR100966749B1 (ko) 2004-05-26 2010-06-30 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
JPWO2006016637A1 (ja) 2004-08-11 2008-05-01 杏林製薬株式会社 新規環状アミノ安息香酸誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
DK1954684T3 (da) 2005-11-15 2014-06-30 Otsuka Pharma Co Ltd Oxazol forbindelse og farmaceutisk sammensætning.
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
CA2643796A1 (en) 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. Polycyclic cinnamide derivatives
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
EP2014652B1 (en) 2006-04-18 2014-08-06 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor
US8653115B2 (en) 2006-06-13 2014-02-18 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
CN100503571C (zh) 2006-07-12 2009-06-24 中国药科大学 四氢异喹啉类衍生物、其制备方法及其医药用途
AU2007277519B2 (en) 2006-07-27 2011-12-22 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US8273738B2 (en) 2006-09-05 2012-09-25 Kyowa Hakko Kirin Co., Ltd. Imidazole derivatives
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
US7795457B2 (en) 2007-02-26 2010-09-14 Kosan Biosciences Incorporated Carbamate compounds
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
EP2176228A1 (en) * 2007-07-04 2010-04-21 NeuroSearch A/S Novel pyrazole derivatives useful as potassium channel modulators
MX2012000434A (es) 2009-07-09 2012-04-11 Crescendo Therapeutics Llc Metodo de sanacion de herida y modulacion de cicatriz.
WO2011069039A1 (en) * 2009-12-04 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
AU2011222531B2 (en) 2010-03-05 2015-03-26 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
WO2012099807A1 (en) * 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
RS56823B1 (sr) * 2011-07-29 2018-04-30 Karyopharm Therapeutics Inc Modulatori nukleusnog transporta koji sadrže hidrazid i njihove upotrebe
CN103842340B (zh) 2011-07-29 2017-09-22 卡尔约药物治疗公司 核转运调节剂及其应用
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
SMT201800686T1 (it) * 2012-05-09 2019-01-11 Biogen Ma Inc Modulatori di trasporto nucleare e loro usi
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
JP6730922B2 (ja) 2013-06-21 2020-07-29 カリオファーム セラピューティクス，インコーポレイテッド 核内輸送調節因子およびその使用
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2015073908A1 (en) 2013-11-15 2015-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method for selecting cancer treatment regimen
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
WO2016025904A1 (en) 2014-08-15 2016-02-18 Karyopharm Therapeutics Inc. Polymorphs of selinexor
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017117529A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11034675B2 (en) 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
EP3565813A1 (en) 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation

Also Published As

Publication number Publication date
BR112014027860A2 (pt) 2017-06-27
ES2794866T3 (es) 2020-11-19
EP3404027B1 (en) 2020-03-04
RS60424B1 (sr) 2020-07-31
EP2858991B1 (en) 2018-08-08
CY1120832T1 (el) 2019-12-11
SG11201407268SA (en) 2015-01-29
BR112014027860B8 (pt) 2024-04-30
EP3663291A1 (en) 2020-06-10
JP2015516434A (ja) 2015-06-11
IN2014DN09434A (es) 2015-07-17
AU2013259384B2 (en) 2016-06-02
KR102223028B1 (ko) 2021-03-03
US20160354347A1 (en) 2016-12-08
US10925859B2 (en) 2021-02-23
PL2858991T3 (pl) 2019-01-31
EA036639B1 (ru) 2020-12-02
CN104428295B (zh) 2017-08-08
AU2019272017A1 (en) 2019-12-19
AU2018201012A1 (en) 2018-03-01
JP6818849B2 (ja) 2021-01-20
MX364992B (es) 2019-05-17
HUE050452T2 (hu) 2021-03-29
SI2858991T1 (sl) 2018-12-31
JP2018012715A (ja) 2018-01-25
KR102163377B1 (ko) 2020-10-08
CL2014003054A1 (es) 2015-05-15
KR102095429B1 (ko) 2020-03-31
JP2020037585A (ja) 2020-03-12
KR20200041986A (ko) 2020-04-22
AU2018201012B2 (en) 2019-12-05
RS58058B1 (sr) 2019-02-28
US10335393B2 (en) 2019-07-02
BR112014027860B1 (pt) 2022-03-08
JP6195909B2 (ja) 2017-09-13
NZ702663A (en) 2017-03-31
SMT202000347T1 (it) 2020-07-08
US20170319551A1 (en) 2017-11-09
DK3404027T3 (da) 2020-06-02
US10722497B2 (en) 2020-07-28
SMT201800686T1 (it) 2019-01-11
ES2702279T3 (es) 2019-02-28
HK1209420A1 (en) 2016-04-01
EP3663291B1 (en) 2024-12-18
CA2872190A1 (en) 2013-11-14
US11318120B2 (en) 2022-05-03
US20210251968A1 (en) 2021-08-19
AU2016222459A1 (en) 2016-09-22
CO7190242A2 (es) 2015-02-19
AU2013259384A1 (en) 2014-12-18
KR20200041984A (ko) 2020-04-22
AU2019272017B2 (en) 2021-05-27
HRP20200876T1 (hr) 2020-09-04
US20200230110A1 (en) 2020-07-23
PT3404027T (pt) 2020-03-30
KR20200115688A (ko) 2020-10-07
US20180289675A1 (en) 2018-10-11
ME03795B (me) 2021-04-20
EA201492050A1 (ru) 2015-07-30
GEP20237477B (en) 2023-03-27
WO2013170068A3 (en) 2014-02-20
US10058535B2 (en) 2018-08-28
SI3404027T1 (sl) 2020-08-31
US9585874B2 (en) 2017-03-07
UA124922C2 (uk) 2021-12-15
CA2872190C (en) 2024-06-25
AU2021221398B2 (en) 2023-08-17
JP2018172444A (ja) 2018-11-08
LT3404027T (lt) 2020-07-10
US20150111893A1 (en) 2015-04-23
US20200038373A1 (en) 2020-02-06
US9096543B2 (en) 2015-08-04
MX2014013551A (es) 2015-01-16
PL3404027T3 (pl) 2020-09-21
EP3404027A1 (en) 2018-11-21
ZA202004892B (en) 2023-03-29
US10617677B2 (en) 2020-04-14
LT2858991T (lt) 2018-11-26
CN104428295A (zh) 2015-03-18
WO2013170068A2 (en) 2013-11-14
DK2858991T3 (en) 2018-11-26
US9861614B2 (en) 2018-01-09
PT2858991T (pt) 2018-12-17
AU2021221398A1 (en) 2021-09-16
KR20150018809A (ko) 2015-02-24
US20190008833A1 (en) 2019-01-10
UA118085C2 (uk) 2018-11-26
US9266843B2 (en) 2016-02-23
CY1123476T1 (el) 2022-03-24
HRP20181838T1 (hr) 2018-12-28
KR20200118240A (ko) 2020-10-14
US20160145246A1 (en) 2016-05-26
JP2021063104A (ja) 2021-04-22
KR102165177B1 (ko) 2020-10-13
HUE040427T2 (hu) 2019-03-28
EP2858991A2 (en) 2015-04-15
US20130317031A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
PE20150128A1 (es) Moduladores del transporte nuclear y usos de los mismos
MX349712B (es) Moduladores del transporte nuclear que contienen hidrazida y sus usos.
ECSP19011216A (es) Inhibidores de piridopyrimdinona cdk2/4/6
NI201400023A (es) Derivados de pirrolopirimidina y purina
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
SV2016005234A (es) Análogos de cortistatina y síntesis y usos de los mismos
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
CR20130646A (es) Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka
DOP2014000204A (es) Compuestos de heterociclilo como inhibidores de mek
UY33921A (es) Oxazinopteridinas y oxazinoptiridinonas n-sustituidas
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
ECSP14013199A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
MX346730B (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
CO7280475A2 (es) Derivados de azaindol que actuan como inhibidores de pi3k
MX2017009824A (es) Triazoles sustituidos y metodos relacionados a estos.
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
CL2017000845A1 (es) Inhibidores de gingipaina de lisina

Legal Events

Date Code Title Description
FG Grant, registration